Join the 'Brimonidine' group to help and get support from people like you.
Alcon Announces FDA Approval of Simbrinza Suspension, a New Beta Blocker-Free, Fixed-Combination Therapy for Glaucoma Patients
Posted 23 Apr 2013 by Drugs.com
Basel, April 19, 2013 – Alcon, the global leader in eye care and a division of Novartis, announces US FDA approval for Simbrinza Suspension, indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.4 Elevated IOP is the only modifiable risk factor for glaucoma. Glaucoma is a group of eye diseases that lead to progressive damage of the optic nerve5 and can result in gradual, irreversible loss of vision, and eventually blindness, if left untreated.6 Glaucoma affects more than 2.2 million Americans7 and is the second-leading cause of preventable blindness worldwide.8 Simbrinza is a fixed-dose combination medication that offers a wide range of treatment possibilities due to its strong efficacy and ability to decrease elevated IOP by 21- 35%.1,2,3 In addition, it is the only available, fixed-dose combination ... Read more